Triple Agonist Peptides: Retatrutide, GLP-3 & What’s Coming Next
Triple agonists combine activity at three hormone-receptor pathways. Retatrutide is the leading clinical example, while newer programs are exploring longer-duration approaches at much earlier evidence stages.
What Is a Triple Agonist?
A triple agonist is one molecule designed to activate three receptor systems: GLP-1, GIP and glucagon.
Why Are People Calling It “GLP-3”?
“GLP-3” is informal shorthand in media, consumer discussion and search behavior. It does not mean a third GLP receptor. “Triple agonist” is the appropriate scientific term here.
Evidence at a Glance
Retatrutide
Phase 3 human clinical evidence.
MBX 6180
Preclinical / IND-enabling; human efficacy has not been established.
Retatrutide — The Clinical Leader
Retatrutide is an investigational once-weekly single-molecule agonist of the GIP, GLP-1 and glucagon receptors. It is not FDA approved.
TRIUMPH-2
Lilly reported up to 20.8% average weight loss at 80 weeks in adults with type 2 diabetes and obesity or overweight.
TRIUMPH-3
Lilly reported up to 22.6% average weight loss at 80 weeks in adults with severe obesity and established cardiovascular disease.
Evidence status: These are sponsor-reported Phase 3 topline results. Detailed TRIUMPH-2 and TRIUMPH-3 results have not yet been published as complete peer-reviewed trial reports. ClinicalTrials.gov confirms the registered trial designs but does not currently provide posted results.
TRIUMPH-3 included exploratory/event analyses of major cardiovascular events, but the reported estimates were imprecise and do not establish cardiovascular-event reduction.
TRANSCEND-T2D-2 — sponsor-reported topline results
On October 28, 2026, Lilly announced results from this Phase 3 randomized, open-label comparison (NCT06260722) in adults with type 2 diabetes inadequately controlled on metformin, with or without an SGLT2 inhibitor. Lilly reported 1,298 participants; the registry lists estimated enrollment rather than a verified final count and has no posted results.
At 80 weeks, efficacy-estimand A1C changes were −2.2 percentage points with retatrutide 9 mg, −2.2 with 12 mg and −1.8 with semaglutide (Ozempic) 2 mg. Weight changes were −19.5% (−20.1 kg), −20.9% (−21.5 kg) and −9.4% (−9.5 kg), respectively. These are trial arms, not dosing recommendations.
The primary objective was A1C noninferiority of 12 mg versus semaglutide 2 mg. Reported A1C superiority for 12 mg and weight superiority for both doses had p<0.001 with family-wise type 1 error control. A1C superiority for 9 mg was nominal p<0.001; 9 mg A1C noninferiority was a multiplicity-controlled key secondary endpoint.
In arm order 9 mg, 12 mg and semaglutide 2 mg, reported diarrhea was 28.3%, 32.7% and 26.4%; nausea 21.2%, 23.8% and 21.3%; constipation 14.2%, 13.1% and 19.8%; vomiting 10.2%, 15.0% and 13.2%; and dyspepsia 10.4%, 8.5% and 11.6%. Dysesthesia occurred in 4.8%, 6.5% and 2.7%; discontinuation due to adverse events in 4.8%, 7.9% and 2.7%. Lilly described most of these events as mild-to-moderate and typically resolving during treatment.
The efficacy estimand assumes participants remained on intervention for 80 weeks, allowing interruptions/modifications, without additional antihyperglycemic medication for more than 14 days; it is not an all-participant treatment-policy estimate. These are sponsor-reported topline findings, not an independently published full trial report. Detailed peer-reviewed publication is pending. Open-label design, incomplete published detail and unresolved long-term safety limit interpretation. These results do not establish cardiovascular-outcome benefit, safety or effectiveness for an approved use, or regulatory approval.
Primary sources: Lilly sponsor announcement and NCT06260722 trial registry.
Regulatory status: Lilly announced plans to submit a U.S. Biologics License Application (BLA) for retatrutide in Q1 2027. A planned filing is not a submitted application or approval. Retatrutide is not FDA approved.
What’s Coming Next? MBX 6180
MBX 6180 is a separate investigational triple-agonist peptide prodrug designed to support potential once-monthly dosing. It is preclinical / IND-enabling and has no established human efficacy.
What Comes After Triple Agonists?
Triple agonists are not the end of multi-receptor research. Researchers are also studying four-target strategies, including NA-931, which has entered human clinical research.
Weekly vs Monthly
Less frequent administration does not establish better efficacy, safety, tolerability or clinical superiority.
What We Still Don’t Know
Retatrutide remains investigational; Lilly has announced a planned Q1 2027 U.S. filing, but no application has been submitted or approved. MBX 6180 has not established human efficacy, and intended monthly pharmacokinetics do not prove clinical superiority.
Frequently Asked Questions
Is Retatrutide FDA approved?
No. It remains investigational. Lilly announced plans for a U.S. BLA submission in Q1 2027, but a planned filing is not a submitted application or approval.
What are the latest Retatrutide Phase 3 results?
Lilly's October 28, 2026 TRANSCEND-T2D-2 announcement reported 80-week efficacy-estimand weight changes of −19.5% with retatrutide 9 mg and −20.9% with 12 mg versus −9.4% with semaglutide 2 mg in adults with type 2 diabetes. A1C superiority for 9 mg was nominal rather than multiplicity-controlled. These are sponsor-reported topline results, not a complete peer-reviewed trial report; see the trial design, safety findings and limitations above.